Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Aldeyra Therapeutics ( (ALDX) ) has shared an update.
On November 13, 2025, Aldeyra Therapeutics announced updates during its 2025 Research & Development Webcast, including the expansion of its RASP platform to address central nervous system diseases and manufacturing updates on reproxalap, a drug candidate for dry eye disease. The webcast highlighted the company’s ongoing clinical trials and regulatory plans, emphasizing the potential impact on its market positioning and stakeholder interests.
The most recent analyst rating on (ALDX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.
Spark’s Take on ALDX Stock
According to Spark, TipRanks’ AI Analyst, ALDX is a Underperform.
Aldeyra Therapeutics faces substantial financial and regulatory challenges, reflected in its low overall score. The lack of revenue and continuous losses are significant risks, compounded by negative technical indicators. The recent FDA response letter adds further uncertainty. However, strong cash reserves and a strategic board appointment provide some potential for recovery if product development succeeds.
To see Spark’s full report on ALDX stock, click here.
More about Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company focused on developing treatments for immune-mediated diseases. The company has a broad immunology pipeline and is working on product candidates like reproxalap for dry eye disease and ADX-2191 for rare retinal inflammatory diseases.
Average Trading Volume: 724,341
Technical Sentiment Signal: Buy
Current Market Cap: $318.9M
For an in-depth examination of ALDX stock, go to TipRanks’ Overview page.